Previous 10 | Next 10 |
home / stock / amam / amam articles
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded down 0.19% to 37,396.28 w...
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transa...
Johnson & Johnson (NYSE:JNJ) has announced a merger with Ambrx Biopharma (NASDAQ:AMAM) that is expected to be completed 2024-H1. Under the term...
MONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $28.00 per...
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitiv...
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. L...
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in toda...
Newly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoi...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...
News, Short Squeeze, Breakout and More Instantly...
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Company Name:
AMAM Stock Symbol:
NYSE Market:
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Website:
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
Ambrx Biopharma Inc. (AMAM) is expected to report $-0.41 for Q4 2023
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Spe...